This study sought to identify baseline characteristics and their regional variation, including those characteristics indicative of disease progression and for the initiation of HBV therapy: HBeAg status, HBV viremia, ALT, and liver fibrosis in HIV/HBV co-infected patients initiating HIV therapy. This evidence concerns the gene GPT and Hepatic fibrosis.